It is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: Unstable angina or non-ST-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). CoPlavix is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or PCI, with or without stent). ST-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. In this population, CoPlavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

headaches or dizziness,Nausea,diarrhoea or constipation,indigestion (dyspepsia),stomach ache or abdominal pain,Nosebleeds,increased bleeding (your blood taking longer to clot for example, when you cut yourself), or easy bruising.

Bleeding, Intracranial hemmorhage

Before taking fexofenadine, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease.

Do not take more than the recommended dosage.

It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Please consult your doctor when taking this medicine if you are pregnant.

Drugs such as Cyclosporin, Quinidine may interact with this drug.